Diversified Revenue ModelA multi‑stream revenue model (product sales, licensing, partnerships, grants) reduces dependence on any single channel, supports recurring royalty income, and creates multiple pathways to commercial scale. This durable diversification helps stabilize cash flows as product adoption expands.

High Gross MarginA gross margin near 64% indicates strong unit economics and potential pricing power for proprietary biomaterials. High gross margins provide a buffer to absorb R&D and SG&A while enabling scalable margin expansion if operating leverage improves and production efficiencies are realized.

Strategic Focus In Regenerative MedicineConcentration in regenerative medicine targets secular growth markets driven by aging populations and unmet clinical needs. A focused product set in wound healing, orthopedics, and drug delivery positions the company to benefit from long‑term structural demand and potential high barriers to entry.

Bears Say

High LeverageA debt/equity ratio of 1.33 signals significant reliance on debt financing. For a company still posting losses, elevated leverage raises refinancing and interest risks, limits flexibility for R&D or commercial investments, and amplifies downside in adverse market conditions.

Negative Operating Cash FlowSustained negative operating cash flow undermines liquidity and forces dependence on external funding. Over the medium term this can constrain product development, commercialization timing and may require dilutive financing or higher debt, impairing long‑term capital allocation options.

Persistent Net Losses & Negative MarginsOngoing net losses and negative profit margins indicate the company has not yet converted attractive gross margins into net profitability. Persistent losses erode equity, limit reinvestment capacity, and increase the time and capital required to reach sustained profitability and positive returns for shareholders.

3-D Matrix News

3-D Matrix and Harvard Achieve Breakthrough in Cardiac Regenerative Therapy

The latest announcement is out from 3-D Matrix ( ($JP:7777) ). 3-D Matrix, Ltd. has achieved a significant...

5M ago

DMTRF FAQ

What was 3-D Matrix Ltd’s price range in the past 12 months?

3-D Matrix Ltd lowest stock price was $0.69 and its highest was $3.96 in the past 12 months.

What is 3-D Matrix Ltd’s market cap?

3-D Matrix Ltd’s market cap is $530.87M.

When is 3-D Matrix Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were 3-D Matrix Ltd’s earnings last quarter?

Currently, no data Available

Is 3-D Matrix Ltd overvalued?

According to Wall Street analysts 3-D Matrix Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does 3-D Matrix Ltd pay dividends?

3-D Matrix Ltd does not currently pay dividends.

What is 3-D Matrix Ltd’s EPS estimate?

3-D Matrix Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 3-D Matrix Ltd have?

3-D Matrix Ltd has 124,027,000 shares outstanding.

What happened to 3-D Matrix Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of 3-D Matrix Ltd?

Currently, no hedge funds are holding shares in DMTRF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

3-D Matrix Ltd

3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was founded in 2004 and is based in Tokyo, Japan.